Pfizer’s Experimental RSV Vaccine Effective, Safe In Late-Stage Clinical Trial Of Older Adults, Early Data Indicate

NBC News (8/25, Lovelace) reports Pfizer’s experimental vaccine RSVpreF for respiratory syncytial virus (RSV) “was nearly 86% effective in preventing severe illness in a late-stage clinical trial of older adults, the company announced in a release Thursda...